Respiratory - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Mesothelioma

Mesothelioma
Protocol Administration at chemotherapy unit level Review Date
Mesothelioma cARBOplatin and pemetrexed Medium June 2022
Mesothelioma cISplatin and pemetrexed Medium August 2024
Mesothelioma ipilimumab and nivolumab
Medium August 2022
Mesothelioma vinORELBine Medium March 2021

Non small cell lung cancer

Non small cell lung cancer
Protocol Administration at chemotherapy unit level Review Date
Advanced or Metastatic nivolumab (flat dosing) Low August 2021
Advanced or Metastatic nivolumab (weight based dosing) Low August 2021
Advanced, metastatic or recurrent pembrolizumab
Low February2022
Non small cell lung cancer adjuvant ciSplatin and pemetrexed
Medium February 2022
Non small cell lung cancer adjuvant cISplatin and vinORELBine Medium August 2024
Non small cell lung cancer definitive cISplatin and etoposide chemoradiation Medium August 2024
Non small cell lung cancer locally advanced definitive cARBOplatin and PACLitaxel chemoradiation Medium February 2024
Non small cell lung cancer locally advanced durvalumab (following chemoradiation) Low August 2022
Non small cell lung cancer locally advanced or metastatic alectinib Low August 2022
Non small cell lung cancer locally advanced or metastatic atezolizumab Low August 2022
Non small cell lung cancer locally advanced or metastatic brigatinib
Low February 2022
Non small cell lung cancer locally advanced or metastatic cARBOplatin and pemetrexed Medium August 2025
Non small cell lung cancer locally advanced or metastatic osimertinib Low August 2022
Non small cell lung cancer metastatic afatinib Low February 2024
Non small cell lung cancer locally advanced or metastatic cARBOplatin and gemcitabine Medium Day 1. Low day 8 August 2024
Non small cell lung cancer locally advanced or metastatic cARBOplatin and PACLItaxel Medium August 2024
Non small cell lung cancer locally advanced or metastatic cARBOplatin and vinORELBine Medium August 2024
Non small cell lung cancer locally advanced or metastatic cARBOplatin and weekly PACLItaxel Medium February 2024
Non small cell lung cancer metastatic cARBOplatin PACLitaxel and pembrolizumab Medium. (moves to low risk after completion of cARBOplatin/PACLitaxel treatment) August 2022
Non small cell lung cancer metastatic cARBOplatin PACLitaxel atezolizumab and bevacizumab Medium (moves to low risk after completion of cARBOplatin/PACLitaxel treatment) August 2023
Non small cell lung cancer metastatic cARBOplatin PACLitaxel ipilimumab and nivolumab
Medium August 2022
Non small cell lung cancer metastatic cARBOplatin, pemetrexed and pembrolizumab Medium August 2022
Non small cell lung cancer locally advanced or metastatic cISplatin and gemcitabine Medium Day 1. Low Day 8 August 2024
Non small cell lung cancer locally advanced or metastatic cISplatin and pemetrexed Medium February 2022
Non small cell lung cancer locally advanced or metastatic cISplatin and vinORELBine Medium August 2024
Non small cell lung cancer locally advanced or metastatic entrectinib
Low August 2022
Non small cell lung cancer locally advanced or metastatic lorlatinib
Low August 2022
Non small cell lung cancer metastatic ciSplatin, pemetrexed and pembrolizumab Medium August 2022
Non small cell lung cancer metastatic DOCEtaxel three weekly Medium August 2024
Non small cell lung cancer metastatic pemetrexed Low1 February 2024
Non small cell lung cancer metastatic vinORELBine (intravenous). The SA Health Cancer Drug Committee endorses the substitution of oral vinORELBine for this single agent protocol for suitable patients Medium August 2024
Non small cell lung cancer metastatic vinORELBine (oral) Low August 2024
Non small cell lung cancer superior sulcus (Pancoast) cISplatin and etoposide chemoradiation pre-operative    Medium February 2024

Small cell lung cancer

Small cell lung cancer
Protocol Administration at chemotherapy unit level Review Date
Small cell lung cancer advanced topotecan (modified) Medium August 2024
Small cell lung cancer extensive disease cARBOplatin and etoposide Medium August 2024
Small cell lung cancer extensive disease cARBOplatin and oral etoposide Medium Day 1. Low day 2 & 3 August 2024
Small cell lung cancer extensive disease cARBOplatin etoposide and atezolizumab
Medium. Moves to low risk after completion of cARBOplatin and etoposide treatment August 2023

Small cell lung cancer extensive disease cARBOplatin etoposide and durvalumab

Medium3 August 2022
Small cell lung cancer extensive disease CAV (CYCLOPHOSPHamide DOXOrubicin vinCRISTine) Medium August 2024
Small cell lung cancer extensive disease ciSplatin and irinotecan Medium August 2023
Small cell lung cancer limited disease cARBOplatin and etoposide Medium August 2024
Small cell lung cancer limited disease cISplatin and etoposide Medium August 2024
Small cell lung cancer limited disease cISplatin and etoposide chemoradiation Medium August 2024

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.